Shares of Threshold Pharmaceuticals (NASDAQ: THLD) jumped up 15% today, bizarrely upon news that its competitor Celgene (CELG) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.